{"id":69346,"date":"2016-12-05T22:07:36","date_gmt":"2016-12-06T03:07:36","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=69346"},"modified":"2016-12-06T10:03:40","modified_gmt":"2016-12-06T15:03:40","slug":"deja-vu-7","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2016\/12\/05\/deja-vu-7\/","title":{"rendered":"d\u00e9j\u00e0 vu…"},"content":{"rendered":"
I ran across this article on a recent drive-by of this month’s journals. It seemed like an anachronism, like something from the past. But more than that, I had an uncanny d\u00e9jà vu feeling about it. It took a while to recall why. Back when I was first looking at clinical trials [2010?], I found where this study had been done, but apparently was never published. I even wrote AstraZeneca <\/font><\/strong>asking about it [receiving no reply]. I had started to work in a clinic where it seemed like everybody I saw was taking Seroquel, and I was trying to figure out why. About that time, the news was full of Veterans suiciding, and the epidemic prescription of Seroquel [for sleep?] was implicated. Apparently the VAH consumption of that drug was off the charts. In our clinic, it took a while to get people off of Seroquel [because it works for sleep]. I thought the risk\/benefit equation did not justify using a neuroleptic for sleep so I gradually changed things [and I learned a lot about Seroquel withdrawal in the process]:<\/div>\n
\n
Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial<\/a> <\/div>\n
by Gerardo Villarreal, Mark B. Hamner, Jos\u00e9 M. Cañive, Sophie Robert, Lawrence A. Calais, Valerie Durklaski, Yusheng Zhai, and Clifford Qualls<\/div>\n
American Journal of Psychiatry<\/font><\/strong>. 2016 173[12]:1205-1212.<\/div>\n\n\n\n\n\n\n
 <\/td>\nReceived<\/font><\/strong>:<\/td>\nJuly 27, 2015<\/td>\n<\/tr>\n
 <\/td>\nAccepted<\/font><\/strong>:<\/td>\nMay 02, 2016<\/font><\/strong><\/td>\n<\/tr>\n
ClinicalTrials.gov Identifier<\/font><\/strong>: NCT00237393<\/a><\/td>\n<\/tr>\n
 <\/td>\nStudy Start Date<\/font><\/strong>:<\/td>\nAugust 2003<\/td>\n<\/tr>\n
 <\/td>\nStudy Completion Date<\/font><\/strong>:<\/td>\nDecember 2007<\/font><\/strong><\/td>\n<\/tr>\n<\/table>\n

<\/p>\n

Objective:<\/font><\/strong><\/em> This was a 12-week randomized, placebo-controlled trial to assess the efficacy of quetiapine monotherapy in the treatment of posttraumatic stress disorder [PTSD].<\/div>\n
Method:<\/font><\/strong><\/em> Eighty patients were randomly assigned to treatment with either quetiapine or placebo. The primary outcome measure was the Clinician-Administered PTSD Scale [CAPS]. Secondary efficacy measures included the CAPS subscales, the Davidson Trauma Scale, the Positive and Negative Syndrome Scale [PANSS], the Clinical Global Impressions [CGI] scales for severity of Illness and improvement, the Hamilton Depression Rating Scale [HAM-D], and the Hamilton Anxiety Rating Scale [HAM-A]. Safety measurements included adverse events, vital signs, the Abnormal Involuntary Movement Scale, the Barnes Akathisia Scale, the Simpson-Angus Scale, and the Arizona Sexual Experiences Scale.<\/div>\n
Results:<\/font><\/strong><\/em> After a 1-week placebo run-in, quetiapine was started at a daily dosage of 25 mg and increased to a maximum of 800 mg; the average was 258 mg [range, 50–800 mg]. Reductions in CAPS total, re-experiencing, and hyperarousal scores were significantly greater for the quetiapine group than for the placebo group. Greater improvements were also observed for quetiapine in scores on the Davidson Trauma Scale, CGI severity and improvement ratings, PANSS positive symptom and general psychopathology subscales, HAM-A, and HAM-D than for placebo. Adverse events were generally mild and expected based on prior studies of quetiapine in this and other patient population. There were no differences in safety measures between groups.<\/div>\n
Conclusion:<\/font><\/strong><\/em> Quetiapine monotherapy was efficacious in the treatment of PTSD. These findings suggest quetiapine as a single agent is effective in treating military PTSD.<\/div>\n
<\/div>\n
<\/div>\n
\n

Presented at the 29th Annual Conference of the Anxiety Disorders Association of America, Santa Anna Pueblo, N.M., March 12–15, 2009, and the 2009 CINP Thematic Meeting, Edinburgh, April 25–27, 2009.<\/font><\/strong><\/em><\/p>\n

Funded by an investigator-initiated grant from AstraZeneca<\/font><\/strong> to Dr. Hamner.<\/em><\/p>\n

Dr. Hamner has current research support from Alkermes and Pfizer; he has been the recipient of research grant support or honoraria and\/or has served as a consultant for the following pharmaceutical companies: Abbott, AstraZeneca<\/font><\/strong>, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Janssen, Lundbeck, Organon, Otsuka, and Sanofi-Synthlabo. Dr. Cañive has received research grant support or honoraria and\/or has served as a consultant for the following pharmaceutical companies: Abbott, AstraZeneca<\/font><\/strong>, Bristol-Myers Squibb, Eli Lilly, Organon, Otsuka, and Sanofi-Synthlabo. The other authors report no financial relationships with commercial interests.<\/em><\/div>\n<\/blockquote>\n
The study met its primary outcome parameters and racked up the requisite p-values and effect sizes to be called a positive study. There was an accompanying editorial. And Dr. Stein was as confused as I was about the almost decade lag time between the end of the actual Clinical Trial [2007] and its publication [2016]. <\/div>\n
\n
Editorial<\/font><\/strong> <\/a><\/div>\n

<\/a><\/p>\n

Adjusting to Traumatic Stress Research<\/a><\/div>\n
by Murray B. Stein <\/div>\n
American Journal of Psychiatry<\/font><\/strong>. 2016 173[12]:1165-1166.<\/div>\n

<\/p>\n

…the study by Villarreal et al., also in this issue, digs up a topic thought to be long dead: the efficacy of atypical antipsychotics for PTSD. Whereas some early, small trials had suggested that atypical antipsychotics, such as olanzapine or risperidone, might be useful adjunctive [to selective serotonin reuptake inhibitors] treatment for PTSD, a large VA Cooperative Study seemed to put the nail in the coffin of that treatment option by failing to show a benefit of adjunctive risperidone on global severity of PTSD. That trial, it should be noted, did show statistically significant [though, it was argued, clinically modest] beneficial effects on hyperarousal symptoms and, in a more recent secondary analysis, sleep disturbance. Moreover, meta-analysis suggests that atypical antipsychotics can be useful in treating PTSD, and clinicians continue to believe they are efficacious and continue to prescribe them for many [up to 20% of] patients with PTSD.<\/div>\n

Against this backdrop of high antipsychotic prescribing for PTSD in the face of limited evidence of efficacy comes this new randomized placebo-controlled trial of quetiapine as monotherapy for military-related PTSD [by Villarreal et al]. Well, not really a new study, but an old study — completed in 2008 — newly published. It is unclear why it took nearly a decade to publish the results of this positive study, but it is timely nonetheless. <\/font><\/strong><\/em>Albeit a fairly small trial that enrolled 80 patients, the results suggest that quetiapine can be useful in the treatment of PTSD, though the authors remind readers that adverse effects of this class of drugs must be considered in the risk-benefit ratio of whether to treat a given individual.<\/p>\n

Whereas clinical practice should rarely be influenced by findings from a single trial, the results of this study should hasten a reinvigoration of research into the safety and efficacy of atypical antipsychotics for the treatment of PTSD. Though we yearn for a future where better and safer drugs for PTSD can be targeted for precisely the patients most likely to benefit from them with the fewest adverse effects, we are constrained to practice medicine in the present. Call it imprecision medicine if you must, but if atypical antipsychotics — administered as monotherapy or as adjunctive therapy — can help some patients with PTSD — then let’s shore up the evidence base for their utility so that we practitioners can feel less stressed about using them.<\/div>\n<\/blockquote>\n
I’m obviously in the "stressed about using them<\/font><\/em>" camp. I doubt this article would’ve changed that, because since then, the cases of Tardive Dyskinesia I’ve seen have been in non-psychotic people who were on antipsychotics for sleep, or augmentation, or unclear reasons. Fortunately, the TD cases aren’t common and usually slowly clear over time [or at least diminish]. But that’s just not a risk I’m willing to take. That wasn’t my main beef with Seroquel. In my hands, it was a lousy antipsychotic drug. I just couldn’t make it work. I reviewed all the FDA studies used for approval, and they were on the shaky side. And beyond that, there was one trial that they just hid from us altogether – Study 15<\/font><\/em>. They put Seroquel up against Haldol in tolerability and relapse prevention and lost both in a big way<\/font><\/strong> [see seroquel VIII: sins of ommission…<\/a>]. That study was actively covered up [see seroquel V: through the looking glass…<\/a>] [don’t miss the ‘smoke and mirrors’ email!<\/font><\/em>]. <\/div>\n
<\/div>\n
That’s when I personally finally began to realize just how corrupt the pharmaceutical industry had become. And I would bet that this month’s anachronistic paper wasn’t published in a timely fashion back in the day because AstraZeneca<\/font><\/strong> was in the news enough already and keeping a low profile. An example [note this news report was at the same time as they were presenting this PTSD study at meetings "<\/strong><\/em><\/font>Presented at the 29th Annual Conference of the Anxiety Disorders Association of America, Santa Anna Pueblo, N.M., March 12–15, 2009, and the 2009 CINP Thematic Meeting, Edinburgh, April 25–27, 2009<\/font><\/strong><\/em>"]: <\/div>\n
\n
A Silenced Drug Study Creates An Uproar<\/a><\/div>\n
Washington Post<\/font><\/strong><\/div>\n
By Shankar Vedantam<\/div>\n
March 18, 2009<\/font><\/strong><\/div>\n

The study would come to be called "cursed," but it started out just as Study 15. It was a long-term trial of the antipsychotic drug Seroquel. The common wisdom in psychiatric circles was that newer drugs were far better than older drugs, but Study 15’s results suggested otherwise.<\/p>\n

As a result, newly unearthed documents show, Study 15 suffered the same fate as many industry-sponsored trials that yield data drugmakers don’t like: It got buried. It took eight years before a taxpayer-funded study rediscovered what Study 15 had found — and raised serious concerns about an entire new class of expensive drugs. Study 15 was silenced in 1997, the same year Seroquel was approved by the Food and Drug Administration to treat schizophrenia…<\/div>\n<\/blockquote>\n
The irony is that while this old trial is small, it’s actually one of Seroquel’s better outings. This post is here just as a reminder of how bizarre the journey has been in the world of psychopharmacology. Once, Seroquel was the blockbuster drug of all times. Now it’s rarely mentioned…<\/div>\n","protected":false},"excerpt":{"rendered":"

I ran across this article on a recent drive-by of this month’s journals. It seemed like an anachronism, like something from the past. But more than that, I had an uncanny d\u00e9jà vu feeling about it. It took a while to recall why. Back when I was first looking at clinical trials [2010?], I found […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-69346","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/69346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=69346"}],"version-history":[{"count":36,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/69346\/revisions"}],"predecessor-version":[{"id":69382,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/69346\/revisions\/69382"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=69346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=69346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=69346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}